X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
Inflammatory breast cancer (IBC) is a highly aggressive subtype of breast cancer that is often characterized by ErbB2 overexpression. ErbB2 targeting is clinically relevant using trastuzumab (anti-ErbB2 antibody) and lapatinib (small-molecule ErbB1/2 inhibitor). However, acquired resistance is a common outcome even in IBC patients who show an initial clinical response, which limits the efficacy of these agents. In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors. A marked decrease in p-ErbB2, p-ErbB1, and downstream signaling was evident in the GW583340-resistant cells (rSUM190 and rSUM149) similar to parental counterparts treated with the drug, suggesting that the primary mechanism of action of GW583340 was not compromised in resistant cells. However, rSUM190 and rSUM149 cells growing in GW583340 had significant XIAP overexpression and resistance to GW583340-mediated apoptosis. Additionally, stable XIAP overexpression using a lentiviral system reversed sensitivity to GW583340 in parental cells. The observed overexpression was identified to be caused by IRES-mediated XIAP translation. XIAP downregulation in rSUM190 and rSUM149 cells using a small-molecule inhibitor (embelin), which abrogates the XIAP/procaspase-9 interaction, resulted in decreased viability, showing that XIAP is required for survival of cells with acquired resistance to GW583340. These studies establish the feasibility of development of an XIAP inhibitor that potentiates apoptosis for use in IBC patients with resistance to ErbB2-targeting agents.
Aird
Katherine M
KM
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Ghanayem
Rami B
RB
Peplinski
Sharon
S
Lyerly
Herbert K
HK
Devi
Gayathri R
GR
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000235:genetics*; D016227:Benzoquinones / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D002277:Carcinoma / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D002478:Cells, Cultured; D015536:Down-Regulation; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005240:Feasibility Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008413:Mastitis / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D013450:Sulfones / Q000627:therapeutic use*; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*
D000970:Antineoplastic Agents; D016227:Benzoquinones; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D013450:Sulfones; D051636:X-Linked Inhibitor of Apoptosis Protein; C551538:GW 583340; C496866:XIAP protein, human; C010945:embelin
J Med Chem. 2004 May 6;47(10):2430-40
15115387
Mol Cancer Ther. 2004 Jun;3(6):699-707
15210856
Cancer Res. 2004 Feb 15;64(4):1293-8
14973058
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):112-20
18032780
Semin Cancer Biol. 2004 Aug;14(4):231-43
15219616
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800
16682622
Cancer Res. 2004 Dec 1;64(23):8558-65
15574762
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
Cell Death Differ. 2006 Feb;13(2):179-88
16322751
Clin Ther. 2008 Aug;30(8):1426-47
18803986
Oncologist. 2008 Oct;13(10):1114-9
18849320
Mol Pharmacol. 2008 Sep;74(3):807-22
18544666
Genes Dev. 1999 Feb 1;13(3):239-52
9990849
Nat Clin Pract Oncol. 2006 May;3(5):269-80
16683005
J Clin Oncol. 2003 Jun 15;21(12):2254-9
12805323
Breast Cancer Res Treat. 2004 May;85(1):13-22
15039594
J Clin Oncol. 2005 Aug 10;23(23):5305-13
15955900
Apoptosis. 2007 Sep;12(9):1543-68
17573556
Br J Cancer. 1999 Dec;81(8):1328-34
10604729
Clin Cancer Res. 2006 Sep 1;12(17):5047-54
16951220
Trends Genet. 2000 Oct;16(10):469-73
11050335
Curr Opin Cell Biol. 2006 Dec;18(6):616-22
16962308
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10607-12
17556544
Oncogene. 2000 Aug 24;19(36):4174-7
10962579
J Biol Chem. 2005 Nov 18;280(46):38599-608
16157589
Cancer Lett. 2006 Feb 8;232(2):123-38
16458110
Oncogene. 2002 Sep 12;21(41):6255-63
12214266
EMBO J. 1996 Jun 3;15(11):2685-94
8654366
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8
12518064
Oncogene. 2003 Nov 24;22(53):8581-9
14634620
Hum Pathol. 2007 Jun;38(6):864-70
17350670
Oncogene. 1998 Dec 24;17(25):3247-59
9916987
J Biol Chem. 2004 Aug 13;279(33):34087-90
15218035
Int J Cancer. 2008 Mar 15;122(6):1324-32
17999412
J Clin Oncol. 1986 Dec;4(12):1765-71
3783202
Nat Cell Biol. 1999 Jul;1(3):190-2
10559907
Cancer. 1980 Jun 1;45(11):2730-7
6769583
J Clin Oncol. 2008 Mar 1;26(7):1066-72
18212337
Cell. 2000 Jan 7;100(1):57-70
10647931
Nat Rev Cancer. 2002 Sep;2(9):647-56
12209154
Nature. 2001 May 17;411(6835):342-8
11357141
Mol Cancer Ther. 2008 Jan;7(1):38-47
18202008
Breast Cancer Res Treat. 2005 Oct;93(3):237-46
16172796
Cell Cycle. 2008 Apr 15;7(8):1036-46
18414036
Oncogene. 2003 Nov 24;22(53):8568-80
14634619
Biochem J. 2009 Feb 1;417(3):765-71
18851715